Olanzapine (Weltruza)
Small molecule
Also known as TV-44749
Evidence outlook
Approved: Schizophrenia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SOLARIS NCT05693935 · Schizophrenia The 675-participant study was randomized, quadruple-blind, and placebo-controlled, with approximately 165 to 169 participants per blinded treatment group. Its primary clinical endpoint, change in PANSS total score at week 8, was significantly better with each TV-44749 dose than with placebo (all adjusted p<0.0001), supporting a strong evidence rating for the blinded efficacy comparison. Registry: NCT05693935 | 3 | Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 (Baseline, Week 8) 2024-03-19 | Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 (Baseline, Week 8): Double-blind: TV-44749 318 mg -21.91 units on a scale (95% CI -25.13 to -18.7) | Double-blind: TV-44749 425 mg -23.44 units on a scale (95% CI -26.52 to -20.36) | Double-blind: TV-44749 531 mg -21.93 units on a scale (95% CI -25.01 to -18.85) vs Double-blind: Placebo -12.17 units on a scale (95% CI -15.34 to -8.99) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (5)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (2)
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Appears in other studies (7)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (2)
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Early phase / not applicable (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Schizophrenia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Olanzapine (Weltruza): this drug | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist) | Reliable signal | NCT05693935: Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 (Baseline, Week 8): Double-blind: TV-44749 318 mg -21.91 units on a scale (95% CI -25.13 to -18.7) | Double-blind: TV-44749 425 mg -23.44 units on a scale (95% CI -26.52 to -20.36) | Double-blind: TV-44749 531 mg -21.93 units on a scale (95% CI -25.01 to -18.85) vs Double-blind: Placebo -12.17 units on a scale (95% CI -15.34 to -8.99) | |
| Aripiprazole (Abilify Maintena) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist) | Reliable signal | NCT03172871: LS mean change from baseline to Week 10 in PANSS Total Score: -33.6 (aripiprazole once-monthly, AOM) vs -34.8 (oral aripiprazole); difference -1.2 (95% CI: -4.1, 1.7), within the pre-defined non-inferiority margin NCT00706654: Impending relapse by week 26: aripiprazole once-monthly 400 mg 7.12% vs oral aripiprazole 10-30 mg 7.76% (non-inferior); low-dose depot reference arm 21.80% | |
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | Partial signal | NCT00712686: Mean change in PANSS Total Score from baseline to Week 6: aripiprazole -24.6 vs olanzapine -29.5 (random regression model); treatment difference 4.9 points, 95% CI 2.2-7.6, exceeding the pre-specified 6-point non-inferiority margin -- aripiprazole did not reach non-inferiority (olanzapine was statistically superior). Aripiprazole showed significantly less weight gain at Week 26: +0.13 kg vs +4.30 kg for olanzapine, and fewer patients with significant weight gain (21% vs 40%, p<.05). | |
| Aripiprazole Lauroxil (Aristada Initio) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Aripiprazole Lauroxil (Aristada) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | Reliable signal | NCT01469039: The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): Aripiprazole Lauroxil 441 mg -20.9 units on a scale (Standard Error 1.39) | Aripiprazole Lauroxil 882 mg -21.8 units on a scale (Standard Error 1.35) vs Placebo -9.8 units on a scale (Standard Error 1.39) | |
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Partial signal | NCT00212771: Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint NCT00212784: Change in total PANSS score (52-week active-controlled trial): asenapine -21.0 vs olanzapine -27.5, difference P<0.0001. missed | |
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | Partial signal | NCT03198078: Change from baseline to Week 6 in PANSS total score: brexpiprazole -22.8 (SE 1.5) vs placebo -17.4 (SE 1.6); least-squares mean difference -5.33, 95% CI -9.55 to -1.10, p=0.014 NCT01396421: Change in PANSS total score at Week 6 vs placebo: brexpiprazole 2 mg treatment difference -8.72; 4 mg treatment difference -7.64 (both statistically significant). | |
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | Reliable signal | NCT01104766: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. (Baseline to Week 6): Cariprazine 3.0 mg -20.2 Units on a Scale (Standard Error 1.5) | Cariprazine 6.0mg -23 Units on a Scale (Standard Error 1.5) vs Placebo -14.3 Units on a Scale (Standard Error 1.5) | Aripiprazole 10.0 mg -21.2 Units on a Scale (Standard Error 1.4) NCT01104779: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline to Week 6): Cariprazine (3-6 mg/Day) -22.8 Units on a Scale (Standard Error 1.6) | Cariprazine (6-9 mg/Day) -25.9 Units on a Scale (Standard Error 1.7) vs Placebo -16 Units on a Scale (Standard Error 1.6) | |
| Clozapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Weak signal | NCT03510325: Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. | |
| Haloperidol | ApprovedUS marketing discontinued | Small molecule | Dopamine D2 receptor (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Iloperidone (Fanapt) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Partial signal | NCT00254202: Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). | |
| Lumateperone (Caplyta) | Approved | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | Partial signal | NCT04959032: Study 304 (NCT04959032), time to relapse during double-blind phase: HR 0.37 (95% CI 0.22-0.65), 63% relapse-risk reduction vs placebo (p=0.0002); relapse rate 16.4% (18 relapses) lumateperone vs 38.6% (44 relapses) placebo NCT02469155: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (6 weeks): Lumateperone 14 mg (ITI-007 20 mg Tosylate) -15 units on a scale (Standard Error 1.27) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) -14.6 units on a scale (Standard Error 1.23) vs Placebo -15.1 units on a scale (Standard Error 1.21) | Risperidone -20.5 units on a scale (Standard Error 1.33) missed | |
| Lurasidone | Approved | Small molecule | Dopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Reliable signal | NCT03465787: Change in PANSS total score at week 6 (prespecified primary analysis in the per-protocol set): -26.42±2.02 lurasidone vs -27.33±2.01 quetiapine XR (adjusted mean±SE); difference -0.91 (95% CI -6.35 to 4.53); lower limit above the -8.99 non-inferiority margin, met. The ITT set analysis also showed non-inferiority. NCT00549718: Change in Total PANSS Score From Baseline to the End of the Double Blind Phase (6 weeks): Lurasidone 40mg -19.2 scores on a scale (95% CI -22.6 to -15.7) | Lurasidone 80mg -23.4 scores on a scale (95% CI -26.9 to -19.9) | Lurasidone 120mg -20.5 scores on a scale (95% CI -24 to -17.1) vs Placebo -17 scores on a scale (95% CI -20.5 to -13.6) | |
| Milsaperidone (VHX-896) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Weak signal | No reviewed efficacy summary in this indication | |
| Olanzapine (Zyprexa Relprevv) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Reliable signal | NCT00088478: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). NCT00320489: Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision) (Baseline up to 104 weeks): Olanzapine Pamoate Depot 644.5 Days (IQR 162 to 740) vs Oral Olanzapine 677.5 Days (IQR 169.5 to 740) missed | |
| Olanzapine (Zyprexa) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Partial signal | NCT03510325: Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 missed | |
| Olanzapine / Samidorphan (Lybalvi) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist) | Reliable signal | NCT03187769: Percent change from baseline in body weight at Week 12: 4.91% ALKS 3831 vs 6.77% olanzapine; least-squares mean difference −1.87 percentage points (95% CI −3.33 to −0.41; p=0.012). NCT02634346: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 (4 weeks): ALKS 3831 -23.9 units on a scale (Standard Error 1.28) vs Olanzapine -22.8 units on a scale (Standard Error 1.29) vs Placebo -17.5 units on a scale (Standard Error 1.32) | |
| Paliperidone (Invega) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | NCT04072575: Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 phase 3 result · pivotal pending | |
| Paliperidone Palmitate (Erzofri) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Partial signal | No reviewed efficacy summary in this indication | |
| Paliperidone Palmitate (Invega Sustenna) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Partial signal | NCT02431702: Treatment failure in Part II (9 months): paliperidone palmitate 29.5% vs oral antipsychotics 24.8%, P=0.377; extended 18-month analysis 28.6% vs 44.4%, P=0.080 (DREaM, Schizophr Res 2022). missed NCT00101634: PANSS total improved vs placebo in all three fixed-dose groups (p=0.02 for 25 and 50 mg equiv., p<0.001 for 100 mg equiv.). | |
| Paliperidone Palmitate (Invega Trinza) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Weak signal | NCT04072575: Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 NCT02713282: Symptomatic remission (Andreasen PANSS criteria) at LOCF/Month 12 endpoint: 172/303 patients, 56.8% (95% CI 51.0-62.4) | |
| Perseris | ApprovedUS marketing discontinued | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Reliable signal | NCT02109562: Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): RBP-7000 90 mg -15.367 units on a scale (Standard Error 1.223) | RBP-7000 120 mg -16.456 units on a scale (Standard Error 1.2073) vs Placebo -9.219 units on a scale (Standard Error 1.2162) | |
| Quetiapine (Seroquel XR) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Weak signal | NCT00640601: Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8) | |
| Quetiapine (Seroquel) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Partial signal | NCT00305422: Global cognition improved vs baseline at week 12 on quetiapine (p<0.01) and risperidone (p<0.05). | |
| Risperidone (Risperdal Consta) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Reliable signal | NCT00253136: Clinical improvement (>=20% PANSS total score reduction): 47% (Risperdal Consta 25mg) vs 17% (placebo); design (randomized, double-blind, placebo-controlled, 25/50/75mg arms, 12 weeks, Nov 1999-Dec 2000) and this was the pivotal FDA-registration trial for Risperdal Consta, matching NCT00253136's CT.gov record exactly. | |
| Risperidone (Risperdal) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Rykindo) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Weak signal | No reviewed efficacy summary in this indication | |
| Risperidone (Uzedy) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Reliable signal | NCT03503318: Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): TV-46000 q1m 13/183 | TV-46000 q2m 23/179 vs Placebo 53/181 | |
| Xanomeline / Trospium Chloride (Cobenfy) | Approved | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | Reliable signal | NCT04738123: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (From baseline up to Week 5): KarXT -20.6 Score on a scale (Standard Error 1.584) vs Placebo -12.2 Score on a scale (Standard Error 1.552) NCT04659161: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (Baseline and Week 5): KarXT -21.2 score on a scale (Standard Deviation 1.652) vs Placebo -11.6 score on a scale (Standard Deviation 1.6) | |
| Ziprasidone | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Partial signal | NCT00403546: Change from baseline in PANSS total score at Week 8, high-dose ziprasidone (320 mg/day) vs standard dose (160 mg/day plus placebo capsules): -8.62 vs -5.48, mixed-model difference -1.37 (95% CI -7.20 to 4.45), p=0.642. No registered primary favoured the high dose; the Simpson-Angus extrapyramidal score was worse on the high dose at Week 2 (difference 1.02, 95% CI 0.08 to 1.95, p=0.033). missed NCT00159770: Ziprasidone non-inferior to the olanzapine/risperidone/quetiapine group on total PANSS (margin 7 units; P<0.0001). | |
| Cariprazine (Chengdu Kanghong) | Phase 3 | Small molecule | Dopamine D3/D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Cariprazine (QLM1016) | Phase 3 | Small molecule | Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Dexmedetomidine (Igalmi) | Phase 3 | Small molecule | Alpha-2 adrenergic receptor (agonist) | Reliable signal | NCT04268303: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score (Baseline and 2 hours): 120 Micrograms — Baseline: 17.5 score on a scale (Standard Deviation 2.46); 2 Hours: -8.4 score on a scale (Standard Deviation 4.83) | 180 Micrograms — Baseline: 17.6 score on a scale (Standard Deviation 2.69); 2 Hours: -10.4 score on a scale (Standard Deviation 4.34) vs Placebo — Baseline: 17.6 score on a scale (Standard Deviation 2.26); 2 Hours: -4.7 score on a scale (Standard Deviation 4.69) NCT05658510: Primary endpoint (SERENITY III Part 1, change from baseline in PEC total score at 2 hours), drug vs placebo: p=0.077, not statistically significant. | |
| Direclidine | Phase 3 | Small molecule | Muscarinic M4 receptor | Partial signal | NCT05545111: PANSS total score at week 6: 7.5-point placebo-adjusted improvement (p=0.011, effect size 0.61) with 20 mg once daily; 18.2-point improvement from baseline | |
| HS-10380 | Phase 3 | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A/5-HT2A receptors (multi-target) | Partial signal | No reviewed efficacy summary in this indication | |
| LB-102 (methylated Amisulpride) | Phase 3 | Small molecule | Dopamine D2/D3 receptor + 5-HT7 receptor | Reliable signal | NCT06179108: Change From Baseline to Week 4 in the PANSS Total Score (Baseline to Day 28 (4 weeks)): LB-102, 50 mg QD -14.28 score on a scale ± 1.097 vs LB-102, 75 mg QD -13.95 score on a scale ± 1.108 vs LB-102, 100 mg -16.08 score on a scale ± 1.906 vs Placebo Comparator -9.27 score on a scale ± 1.078; p=0.0009 (LB-102, 50 mg QD vs Placebo Comparator), p=0.0022 (LB-102, 75 mg QD vs Placebo Comparator), p=.0017 (LB-102, 100 mg vs Placebo Comparator) | |
| Loxapine (Adasuve) | Phase 3 | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Reliable signal | NCT00628589: Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92) | |
| Olanzapine / Samidorphan (Qilu) | Phase 3 | Small molecule | Dopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist); mu-opioid receptor (antagonist), Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Roluperidone | Phase 3 | Small molecule | Sigma-2 receptor complex, Serotonin 5-HT2A receptor (antagonist / inverse agonist) | Partial signal | NCT03397134: Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) (Baseline, Week 2, Week 4, Week 8, and Week 12): Roluperidone 32 mg — Baseline: 25.2 score on a scale (Standard Deviation 3.43); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.22); Change from Baseline to Week 4: -2.6 score on a scale (Standard Deviation 2.57); Change from Baseline to Week 8: -3.4 score on a scale (Standard Deviation 3.49); Change from Baseline to Week 12: -3.7 score on a scale (Standard Deviation 3.2) | Roluperidone 64 mg — Baseline: 25.3 score on a scale (Standard Deviation 3.26); Change from Baseline to Week 2: -1.7 score on a scale (Standard Deviation 2.47); Change from Baseline to Week 4: -2.8 score on a scale (Standard Deviation 2.92); Change from Baseline to Week 8: -3.8 score on a scale (Standard Deviation 3.32); Change from Baseline to Week 12: -4.5 score on a scale (Standard Deviation 3.85) vs Placebo — Baseline: 24.3 score on a scale (Standard Deviation 3.01); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.46); Change from Baseline to Week 4: -1.8 score on a scale (Standard Deviation 2.99); Change from Baseline to Week 8: -2.8 score on a scale (Standard Deviation 3.44); Change from Baseline to Week 12: -3.5 score on a scale (Standard Deviation 3.97) missed | |
| Ulotaront | Phase 3 | Small molecule | TAAR1 (trace amine-associated receptor 1) | Partial signal | NCT04092686: Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): SEP-363856 75mg -16.4 score on a scale (Standard Error 1.49) | SEP-363856 100mg -18.1 score on a scale (Standard Error 1.5) vs Placebo -14.3 score on a scale (Standard Error 1.47) missed NCT04072354: Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): Adults: SEP-363856 50mg -16.9 score on a scale (Standard Error 1.57) | Adults: SEP-363856 75mg -19.6 score on a scale (Standard Error 1.56) vs Adults: Placebo -19.3 score on a scale (Standard Error 1.55) missed | |
| ANAVEX3-71 | Phase 2 | Small molecule | Sigma-1 receptor / muscarinic receptor (dual) | Partial signal | NCT06245213: ANAVEX3-71-SZ-001 (NCT06245213) achieved its primary endpoint: ANAVEX3-71 was safe and well-tolerated, with no serious TEAEs and no severe TEAEs in either Part A or Part B. | |
| Balipodect (TAK-063) | Phase 2 | Small molecule | Phosphodiesterase 10A (PDE10A) | Partial signal | NCT02477020: Change From Baseline in the Positive and Negative Symptom Scale (PANSS) Total Score at Week 6 (Baseline and Week 6): TAK-063 -19.54 score on a scale (Standard Error 2.412) vs Placebo -14.08 score on a scale (Standard Error 2.474) missed | |
| Betovumeline / Fesoterodine (ML-007C-MA) | Phase 2 | Small molecule | Muscarinic M1 and M4 receptors (agonist) | Partial signal | NCT07038876: PANSS total score change at week 5 vs placebo (mITT): 210/3 mg BID, LS mean difference -4.5 points, Cohen's d 0.37, p=0.015, met. 330/6 mg QD, numerical improvement, not statistically significant (no figure given), missed. | |
| Brenipatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| CPL500036 | Phase 2 | Small molecule | PDE10A | Reliable signal | NCT05278156: Change from baseline in PANSS positive subscale at Day 28 (Week 4): 20 mg dose improved 3.7 points (p<0.001, Cohen's d=0.73); 40 mg dose improved 6.3 points (p<0.001, Cohen's d=1.38) | |
| Emraclidine | Phase 2 | Small molecule | Muscarinic M4 receptor | Partial signal | NCT05227703: Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline through Week 6): Emraclidine 15mg QD -18.5 score on a scale (95% CI -22 to -15) | Emraclidine 30mg QD -14.2 score on a scale (95% CI -17.5 to -10.8) vs Placebo -16.1 score on a scale (95% CI -19.4 to -12.8) missed | |
| GXV813 | Phase 2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| LY03020 | Phase 2 | Small molecule | 5-HT2C/TAAR1 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| NBI-1117570 | Phase 2 | Small molecule | Muscarinic M1 and M4 receptors (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Tazbentetol (SPG302) | Phase 2 | Small molecule | Dendritic spine density | not yet graded | No reviewed efficacy summary in this indication | |
| Ublituximab (Briumvi) | Phase 2 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| VV119 | Phase 2 | Small molecule | Dopamine and serotonin receptors (multi-target antipsychotic) | not yet graded | No reviewed efficacy summary in this indication | |
| Cariprazine Long-Acting Injection (Mapi Pharma) | Phase 1/2 | Small molecule | Dopamine D3/D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| JX11502MA | Phase 1/2 | Small molecule | Dopamine D3/D2 receptor (partial agonist) | Weak signal | NCT05233657: JX11502MA was generally well tolerated at a single dose of 0.25 to 3 mg. The most common treatment-emergent adverse events were somnolence (56.3%), nausea (21.9%), dizziness (18.8%), vomiting (18.8%) and hiccups (18.8%). | |
| Aticaprant | Phase 1 | Small molecule | Kappa-opioid receptor (inhibitor), Kappa opioid receptor (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Brexpiprazole Long-Acting Injection (Kelun) | Phase 1 | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| HS-10509 | Phase 1 | Small molecule | — | Partial signal | No reviewed efficacy summary in this indication | |
| LY03017 | Phase 1 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist), 5-HT2A/5-HT2C, 5-HT2A/2C receptor | Weak signal | No reviewed efficacy summary in this indication | |
| NTX-253 | Phase 1 | Small molecule | Muscarinic M4 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (QUAR) | Phase 1 | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Weak signal | No reviewed efficacy summary in this indication | |
| SEP-380135 | Phase 1 | Small molecule | — | Weak signal | No reviewed efficacy summary in this indication |
Large race: only the 60 furthest-along competitors are listed; 8 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent